Coronary disease & ACSRandomised controlled trial
Percutaneous Coronary Intervention (PCI) in Patients Undergoing Transcatheter Aortic-Valve Implantation
- Randomised controlled trial
- international
- 1:1 randomisation
Authors' conclusion
Among patients with coronary artery disease who were undergoing TAVI, PCI was associated with a lower risk of a composite of death from any cause, myocardial infarction, or urgent revascularization at a median follow-up of 2 years than conservative treatment.
Study context
- Population
- Severe symptomatic AS with ≥1 coronary stenosis (FFR ≤0.80 or diameter stenosis ≥90%) undergoing transcatheter aortic-valve implantation (TAVI)
- Participants
- 455 participants
- Comparison
- PCI vs conservative treatment in patients undergoing TAVI
- PCIn = 227
- Conservative treatmentn = 228reference
- Primary endpoint
- MACE:
- Death from any cause
- MI
- Urgent revascularization
- Follow-up
- Median 2 years
Primary result
As reported in the abstract
median follow-up 2 years (IQR 1 to 4)
Hazard ratio
0.71
95% CI 0.51–0.99
P = 0.04
Events by treatment group
PCI vs Conservative treatment
HR 0.71 (95% CI 0.51–0.99); P = 0.04
Safety
| Outcome | PCI | Conservative treatment | HR (95% CI) | |
|---|---|---|---|---|
| Bleeding event | 28% | 20% | 1.51 (1.03–2.22) | |
| 0.512Hazard ratio (log scale) |
- PCI procedure-related complications
- 3% · 7 of 227
Original publication
PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation. N Engl J Med. Published 31 August 2024. doi:10.1056/nejmoa2401513
Summarised from the published abstract; every number is checked against it